Fed Governor Adriana Kugler to resign
WESTBROOK, Maine—Anne M. Szostak, a director at IDEXX Laboratories Inc. (NASDAQ:IDXX), recently sold 3,000 shares of the company’s common stock. The shares were sold at an average price of $465.945, totaling approximately $1.4 million. The transaction comes as IDEXX, with a market capitalization of $38 billion, trades at 43 times earnings, significantly above industry averages according to InvestingPro data. Following this transaction, Szostak retains ownership of 3,061 shares through the Trust of M. Anne Szostak, of which she is the settlor and trustee. This transaction was reported in a Form 4 filing with the Securities and Exchange Commission on February 10, 2025. The stock currently trades near its 52-week low of $398.50, with analysts setting a high target of $566. InvestingPro analysis shows the company maintains a "GREAT" financial health score, with strong profitability metrics and moderate debt levels. Get access to 12 additional exclusive ProTips and comprehensive valuation analysis with an InvestingPro subscription.
In other recent news, IDEXX Laboratories has been the subject of attention from analysts at BTIG and Stifel following its Q4 performance that surpassed expectations in both earnings and revenue. BTIG analyst Mark Massaro raised the price target for IDEXX from $500 to $530, maintaining a Buy rating on the stock. Similarly, Stifel analysts adjusted their price target for IDEXX shares, increasing it to $460 from the previous $440, while keeping a Hold rating.
The company’s Q4 results showed a 13% year-over-year increase in earnings per share, a 12% year-over-year growth in consumables, and a 140 basis point gross margin expansion. Despite the challenges posed by a decrease in pet visits, IDEXX’s management has been commended for their adept handling of the business.
In addition to the Q4 performance, IDEXX has provided a broad guidance range for 2025, with the midpoint suggesting a 12.5% year-over-year growth in earnings per share. The company also plans to place 4,500 InVueDx systems throughout the year, which is expected to contribute to revenue growth. These recent developments indicate a positive outlook for IDEXX Laboratories.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.